Data show teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for patients treated with four or more lines of prior therapy based on results from the Phase…